Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 16, 2018Journal of NeuroinflammationOpen Access

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor

View Full Paper
Ask AI
Bookmark
Share

Authors

CGConcepción GarcíaUniversidad Complutense de MadridMGMaría Gómez‐CañasUniversidad Complutense de MadridSBSonia BurgazUniversidad Complutense de Madrid

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

García et al. (2018) studied this question.

synapsesocial.com/papers/6aace6931b7b2ec23c0cfa56https://doi.org/10.1186/s12974-018-1060-5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Formyl-methionyl-leucyl-phenylalanine–Induced Dopaminergic Neurotoxicity via Microglial Activation: A Mediator between Peripheral Infection and Neurodegeneration?2008 · 46 citations
  2. 2From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets2010 · 142 citations
  3. 3Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice2009 · 99 citations
  4. 4Peroxisome Proliferator‐Activated Receptor <i>β</i>/<i>δ</i> in the Brain: Facts and Hypothesis2008 · 78 citations
  5. 5GW9662, a potent antagonist of PPAR<i>γ</i>, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR<i>γ</i> agonist rosiglitazone, independently of PPAR<i>γ</i> activation2004 · 192 citations